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Abstract 
In the UK, approximately 1,800 children are diagnosed with cancer every year. Paediatric cancers are 
very diverse and differ from adult tumours at both the histological and molecular level. The majority of 
childhood cancers are comprised of haematological malignancies, central nervous system tumours, 
embryonal tumours (retinoblastoma, neuroblastoma, nephroblastoma) and sarcomas. Whilst 
paediatric cancer is rare it is still one of the leading causes of death for children. Due to its rarity, the 
prevalence and variety of the predisposing mutations remains largely unknown. However, the advent 
of next generation sequencing over the past decade has seen our molecular understanding of 
childhood cancers advance significantly. This review gives an overview on the aetiology of paediatric 
cancer and how NGS is helping to advance our understanding of the molecular basis of paediatric 
cancers to improve diagnosis, prognosis and treatment of paediatric cancer patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Childhood cancer is used to describe cancers that arise before the age of 15 years. Cancer is one of 
the leading causes of death for children. Up to 2% of paediatric cancers are documented in 
developing countries whereas in Europe and North America, childhood cancers give rise to less than 
0.5% of all cancer cases. 1 In the UK alone there are approximately 1,800 children diagnosed with 
cancer every year which equates to 5 children every day having a cancer diagnosis; furthermore, 
around 230 children die each year from cancer – more than four children each week. 2 
Paediatric cancers are very diverse and differ from adult tumours at both the histological and 
molecular level. 3 The majority of childhood cancers are comprised of haematological malignancies, 
central nervous system tumours, embryonal tumours (retinoblastoma, neuroblastoma, 
nephroblastoma) and sarcomas (Figure 1). Carcinomas, which are the most common type of cancer 
in adults accounts for less than 5% of children’s cancer.4 
 
 
Figure 1.  Average number of childhood cancer cases diagnosed per year in children aged 0-14 from 
2006-2008 in the UK. 2 
 
Aetiology 
The aetiology of childhood cancers is still unknown due to the rarity of the disease and many reports 
in the literature are contradictory. However, as with adult cancers; combinations of factors, both 
extrinsic and intrinsic, are believed to play a role.  
Extrinsic risk factors 
Exposure to high dose radiation and prior chemotherapy are the only two extrinsic factors accepted to 
cause cancer in children. Other extrinsic factors believed to contribute to paediatric cancers include 
lack of exposure to infections. Leukaemia, the most common form of childhood cancer, primarily 
arises as a result of acquired, rather than, genetic changes with Greaves 5 proposing that delayed 
exposure to childhood infections actually causes the immune system to function abnormally; giving 
rise to an increased risk of paediatric leukaemia. Maternal smoking and alcohol consumption are also 
cited as playing a role. Derivatives of tobacco have been identified in placental tissue, foetal blood, 
the urine of newborns and also in the breast milk of mothers who smoke. 6 However, studies looking 
at the effect of maternal smoking and paediatric cancer are contradictory. One such study carried out 
by Stjernfeldt et al, (1986) 7 showed a dose-response relationship between the number of cigarettes 
smoked on a daily basis by the mother and the risk of cancer in the child. A more recent study has 
shown that whilst there is no association between childhood cancers and smoking mothers in general, 
there was an association between maternal smoking and retinoblastoma. 8 Rumrich et al, (2016) 9 
carried out a meta-analysis using 62 studies and concluded maternal smoking is only associated with 
nervous system cancers. Finally, de Smith et al, (2017) 10 conducted a study on tobacco smoke 
exposure and the associated risk of childhood acute lymphoblastic leukaemia to determine if tobacco-
smoke exposure influences leukaemogenic genomic deletions. They found total number of deletions 
was positively associated with tobacco smoke exposure in smoking mothers and also a dose 
response relationship with paternal smoking during pre-conception and deletion number.  Parental 
smoking is not the only risk factor for childhood cancers. Scientist have also assessed the effect of 
parental alcohol consumption on childhood cancers.  As with smoking, results are inconsistent or 
contradictory. For example, a study conducted by Ferreira et al, (2015) 11 suggests there is no 
association with maternal alcohol intake during pregnancy and increased risk of childhood cancers, 
whilst a study by Latino-Martel, et al (2010) 12 argues that maternal alcohol consumption is a risk 
factor. But why is there so much contradiction between these studies and extrinsic risk factors? The 
majority of the studies are case-control studies and parental interview which are susceptible to recall 
and selection bias.13 It also needs to be remembered that even in the most common childhood 
cancers such as leukaemia and CNS tumours, where accumulation of sufficient data allows for meta-
analysis to be conducted, bias can be introduced  by researchers based on what is or is not reported 
and by the diversity of the clinical trials. 
Intrinsic risk factors 
It has been postulated that the risk of childhood cancer is linked to increasing birth weight (birth 
weights > than 4000g/ 8.8lbs. 14 Several studies have shown cancer incidence rises with increasing 
birth weight; with one such study reporting an association with increased risk of paediatric cancer and 
high birth weight is strongest in children under 2 years of age. 15 Increased birth weight has been 
associated with childhood cancers such as leukaemia, neuroblastoma, astrocytomas and Wilms 
tumour and one reason which has been put forward to explain this association is that of growth factor 
pathways/growth hormone exposure.  One study has attributed the positive association of high birth 
weight and childhood cancer to high levels of circulating insulin-like growth factor-1 (IGF-1); 
suggesting that the transforming event occurs in utero and as a result, high levels of IGF-1 may act on 
already genetically altered cells to provide them with a proliferative advantage. 14 Spector et al, (2015) 
13 provide a more basic reasoning for the association between birth weight and paediatric cancer as 
potentially being down to the greater number of cells that could be at risk for carcinogenic 
transformation. However, the genetic reasoning behind this was not given. Another reason put 
forward by researchers is based on advancing parental age attributing to increased childhood cancer 
risk.  A pooled case-controlled study of 17,672 cancer cases in children diagnosed between the ages 
of 0-14 showed maternal age was associated with a linear increase in the risk of childhood cancers 
with an 8% increase per 5-year increment of maternal age for cancers such as leukaemia, lymphoma, 
CNS, neuroblastoma, Wilms’ tumour, bone tumours and soft tissue sarcomas. However, this 
increased risk was not seen for retinoblastoma, hepatoblastoma or germ cell tumours (Johnson et al, 
2009). 16 A previous study by Yip & Czene (2006) 17 conducted a population-based cohort study (~4.3 
million children) on the risk of parental age on five childhood cancers (leukaemia, retinoblastoma, 
non-Hodgkin’s lymphoma, Wim’s tumour and CNS). The study split the cohort into two diagnostic age 
groups; <5 and 5-14 years and concluded that advanced parental age was associated with an 
increased risk of early childhood cancer when children were 5 years of age or younger, with the oldest 
maternal age group (>40) exhibiting an elevated risk of retinoblastoma.  The contradiction between 
the studies with regards to maternal age and retinoblastoma may come down to study design, 
environmental influences and sample sizes across the maternal age ranges; to name but a few 
confounding factors. Regardless of some contradictory studies, it is accepted that increasing parental 
age influences cancer risk in children. It is believed to occur due to increased mutation frequencies in 
paternal germ cells and increased frequencies of chromosomal aberrations during the maturation of 
maternal germ cells. Aging has also been hypothesised to change physiological parameters, such as 
estrogens levels, which may also induce the risk of childhood cancer. 
 
 
Genetic Factors 
The most obvious risk factor for paediatric cancer is an underlying genetic component. Research has 
progressed from Sanger sequencing, whereby a maximum of 96 (800bp) sequences could be 
analysed, to sequencing millions of DNA fragments; furthermore, we are now able to detect, not just 
point mutations, but also copy number changes, insertions, deletions and translocations. An additional 
and very important aspect of next generation sequencing (NGS) is the ability to detect variants in 
small subpopulations of cells, which would go undetected with Sanger sequencing due to the low 
copy number, yet may be important in terms of cancer recurrence or treatment resistance. 18 NGS can 
broadly be divided into whole genome sequencing (WGS) or whole exome sequencing (WES). As the 
names suggest, WGS involves sequencing the entire genome and identify variations in any part of an 
individuals’ genome. WES is concerned with sequencing/analysing only the exons in an individuals’ 
genome; in other words, the protein or RNA coding regions (Figure 2). The exome represents less 
than 2% of the entire genome, yet contains ~85% of all known disease-causing mutations. Thus, for 
many researchers and clinicians, WES is seen as the most cost effective and efficient method to 
employ. However, it can be argued that WES could miss regions of interest or variation outside the 
exome that could alter gene activity and protein production.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Whole Genome Sequencing involves sequencing the entire genome to ascertain variations 
in any part of an individuals’ genome, whereas Whole Exome Sequencing involves sequencing only 
the coding regions of an individuals’ genome (adapted from GenomixLab, 2019). 19 
 
Whilst the prevalence and variety of predisposing mutations in paediatric cancers remains largely 
unknown, 20 the advent of NGS over the past decade has seen our molecular understanding of 
childhood cancers advance significantly.  
In 2010 the Paediatric Cancer Genome Project was launched and to date, the complete genomes of 
both tumour and normal cells from more than 800 patients have been sequenced with many of their 
findings published in the scientific literature. Two studies which demonstrate some of these findings 
are published by Huether et al, (2014) 21 and Grobner et al, (2018). 3  Studies on paediatric cancers 
have shown that genes involved in epigenetic regulation are mutated at a high frequency. Thus, 
Huether et al, sequenced 633 epigenetic regulatory genes from 1020 paediatric cancers, 
encompassing 21 different cancer sub-types arising in solid tumours, brain tumours and leukemias. 
From this study, they found 16 genes (e.g. H3F3A, CREBBP, USP7) most frequently mutated and a 
marked variation in the frequency of mutations across the three tumour classes; providing further 
understanding of the genetic/epigenetic variation in paediatric tumours. In the study by Grobner et al, 
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reads 
DNA 
Exon Exon Exon 
Short 
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3 961 tumours representing 24 paediatric sub-types were sequenced. The authors found that the 
mutation rate in the paediatric tumours was 14 times lower than that of adult tumours, pathogenic 
germline variants were found in 7.6% of the cohort with most variants found in DNA repair genes from 
mismatch (MSH2, MSH6, PMS2) or double—stand break repair (p53, BRCA2, CHEK2) They also 
found 453 potential drug targets in 59 genes with further analysis suggesting that 52% of all primary 
paediatric tumours may harbour a potential drug target.  
A further study, conducted by Ma et al, 2018, 22 sequenced the genomes of 1699 paediatric 
leukaemia’s and solid tumours. The authors identified 142 “driver genes” (a gene whose mutations 
increase the growth of a cell) of which, only 45% matched those found in adult cancer studies - 
deletions occurring in CDKN2A were found at the highest frequency. An interesting finding of MA’s 
study was that whilst the percentage of tumours with point mutations in driver genes was highly 
consistent between whole-genome sequencing (WGS) and whole-exome sequencing (WES), WGS 
can also detect copy number alterations, which are frequently driver events for paediatric cancers. 
However, when neuroblastomas were analysed by WGS, 72% of the tumours were found to have 
driver mutations compared to just 26% of those analysed by WES; highlighting that perhaps there is a 
need to perform WGS rather than WES when trying to understand the molecular landscape.   
These studies represent just the tip of the iceberg in terms of “discovery” sequencing, but what does 
all this mean for clinicians? After all, discovery sequencing studies are not designed with the needs of 
the clinic in mind and do not assess the ability to analyse and interpret sequencing results at the 
patient-level that will ultimately inform approaches to patient diagnosis, treatment and care .23  
Furthermore, the mere genomic detection of variants is not adequate for a clinical setting. It is 
necessary to determine whether variants are benign, likely benign, pathogenic, likely pathogenic or of 
uncertain clinical significance. 18  WGS can unearth numerous genetic variations but how can we tell 
which variants are clinically relevant? Reliable interpretation of variants requires experience, 
validation and skilled bioinformaticians to analyse the NGS data.  24 In addition, the vast volume of 
sequence data generated (millions if not billions of reads per run) gives rise to bioinformatics 
challenges in terms of data storage, quality control, assembly of the data and annotation. 25 
However, studies carried out in the clinical setting testify to the advantages of NGS over more 
traditional methods such as Sanger. An example of one such study is that by Oberg et al, (2016) 26 
who sought to determine the clinical utility of genomic sequencing in standard clinical practice for 
paediatric cancer and haematological disorders. The authors performed WES of patient-matched 
turmour-normal samples and RNA sequencing (RNA-seq) of tumour samples to identify variants, 
gene expression, fusion transcripts and CNVs (copy number variants). From their study, they found 
38% of patients had a targetable genomic alteration and matched therapy, based on these genomic 
findings, was administered to 16% of the patients. Genomic sequencing also allowed the molecular 
diagnosis of 23 patients and contributed to the prognostic and pharmacogenomics recommendations 
of 32 patients. The authors also reported how genomic sequencing identified a STAT5B mutation in a 
5-year old girl who had been diagnosed with T-cell acute lymphoblastic leukaemia, the identification of 
this STAT5B mutation helped inform and ultimately change the patients’ diagnosis to gamma-delta T-
cell lymphoma. Furthermore, germline variations which held clinical significance were found in 20% of 
patients; allowing them to be referred for genetic counselling, along with the additional consideration 
for future cancer screening in the patients and their families. 
An article published in BMJ 27 reports that England will start offering WGS to all children in 2019 as a 
strategy to offer comprehensive and precise diagnosis in a move towards personalised medicine in a 
bid to reduce the use of unnecessary and harmful drugs (Figure 3).  
 
 
 Figure 3. NGS is increasingly being used to develop personalised therapy to reduce treatment toxicity 
and non-responsiveness. 28 
Although it is still difficult to predict which child is at the greatest risk of chemotherapy-related toxicity 
and/or non-response WGS studies have been conducted that have shed light on genetic variants in 
genes not previously associated with drug toxicity or efficacy. 28 Yang et al, (2009) 29 conducted a 
study on paediatric acute lymphoblastic leukaemia to assess the effect of gene variants in response 
to therapy. WGS was employed to investigate the treatment response of 487 children. Whilst WGS 
identified 102 germline variants, 5 SNPs (single nucleotide polymorphisms) were found in interlukin 
15, a cytokine shown in vitro to protect haematological cancers from glucocorticoid induced apoptosis. 
A more recent study conducted by Abaji et al, 2018, 30 conducted WES to identify genetic markers 
associated with vincristine-induced peripheral neuropathy (VIPN) in childhood acute lymphoblastic 
leukaemia. The authors found germline variants in SYNE2, MRPL47 and BAHD1 that were linked to 
increased risk of VIPN. 
 
Conclusion 
Paediatric cancer, whilst rare, it is still one of the leading causes of death for children and the 
molecular basis for these childhood cancer remains largely unknown. However, with research such as 
the Paediatric Cancer Genome Project, coupled with NGS, our understanding of paediatric cancer 
has made great strides – and with it, our ultimate goal of achieving more effective and individualised 
treatment regimens.  
References 
 
1. Sullivan R, Kowalczyk JR, Agarwal B, et al. New policies to address the global burden of childhood 
cancers. Lancet Oncol 2013;14(3):e125-35. doi: 10.1016/S1470-2045(13)70007-X [published 
Online First: 2013/02/20] 
2. Cancer Research UK. Children's Cancer Statistics 2018 [Available from: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers. 
3. Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across 
childhood cancers. Nature 2018;555(7696):321-27. doi: 10.1038/nature25480 [published 
Online First: 2018/02/28] 
4. Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the 
treatment of childhood cancer: lessons from high-income countries. Lancet Oncol 
2013;14(3):e95-e103. doi: 10.1016/S1470-2045(13)70010-X [published Online First: 
2013/02/20] 
5. Greaves MF. Aetiology of acute leukaemia. Lancet 1997;349(9048):344-9. 
6. Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010;36(4):286-97. doi: 
10.1016/j.ctrv.2010.02.004 [published Online First: 2010/03/12] 
7. Stjernfeldt M, Berglund K, Lindsten J, et al. Maternal smoking during pregnancy and risk of 
childhood cancer. Lancet 1986;1(8494):1350-2. 
8. Stavrou EP, Baker DF, Bishop JF. Maternal smoking during pregnancy and childhood cancer in New 
South Wales: a record linkage investigation. Cancer Causes Control 2009;20(9):1551-8. doi: 
10.1007/s10552-009-9400-5 [published Online First: 2009/07/16] 
9. Rumrich IK, Viluksela M, Vähäkangas K, et al. Maternal Smoking and the Risk of Cancer in Early Life 
- A Meta-Analysis. PLoS One 2016;11(11):e0165040. doi: 10.1371/journal.pone.0165040 
[published Online First: 2016/11/08] 
10. de Smith AJ, Kaur M, Gonseth S, et al. Correlates of Prenatal and Early-Life Tobacco Smoke 
Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic 
Leukemia. Cancer Res 2017;77(7):1674-83. doi: 10.1158/0008-5472.CAN-16-2571 [published 
Online First: 2017/02/15] 
11. Ferreira JD, Couto AC, Emerenciano M, et al. Maternal Alcohol Consumption during Pregnancy 
and Early Age Leukemia Risk in Brazil. Biomed Res Int 2015;2015:732495. doi: 
10.1155/2015/732495 [published Online First: 2015/05/18] 
12. Latino-Martel P, Chan DS, Druesne-Pecollo N, et al. Maternal alcohol consumption during 
pregnancy and risk of childhood leukemia: systematic review and meta-analysis. Cancer 
Epidemiol Biomarkers Prev 2010;19(5):1238-60. doi: 10.1158/1055-9965.EPI-09-1110 
13. Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. 
Pediatr Clin North Am 2015;62(1):11-25. doi: 10.1016/j.pcl.2014.09.013 [published Online 
First: 2014/10/18] 
14. Ross JA. High birthweight and cancer: evidence and implications. Cancer Epidemiol Biomarkers 
Prev 2006;15(1):1-2. doi: 10.1158/1055-9965.EPI-05-0923 
15. Daling JR, Starzyk P, Olshan AF, et al. Birth weight and the incidence of childhood cancer. J Natl 
Cancer Inst 1984;72(5):1039-41. 
16. Johnson KJ, Carozza SE, Chow EJ, et al. Parental age and risk of childhood cancer: a pooled 
analysis. Epidemiology 2009;20(4):475-83. doi: 10.1097/EDE.0b013e3181a5a332 
17. Yip BH, Pawitan Y, Czene K. Parental age and risk of childhood cancers: a population-based 
cohort study from Sweden. Int J Epidemiol 2006;35(6):1495-503. doi: 10.1093/ije/dyl177 
[published Online First: 2006/09/28] 
18. Calabria I, Pedrola L, Berlanga P, et al. The new challenge in oncology: Next-generation 
sequencing and its application in precision medicine. An Pediatr (Barc) 2016;85(5):273.e1-
73.e7. doi: 10.1016/j.anpedi.2016.05.006 [published Online First: 2016/10/31] 
19. GenomixLab. Whole Genome Sequencing 2019 [Available from: 
http://www.genomixlab.com/human-genome-sequencing/#.XIZ1ViL7RhE. 
20. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. 
N Engl J Med 2015;373(24):2336-46. doi: 10.1056/NEJMoa1508054 [published Online First: 
2015/11/18] 
21. Huether R, Dong L, Chen X, et al. The landscape of somatic mutations in epigenetic regulators 
across 1,000 paediatric cancer genomes. Nat Commun 2014;5:3630. doi: 
10.1038/ncomms4630 [published Online First: 2014/04/08] 
22. Ma X, Liu Y, Alexandrov LB, et al. Pan-cancer genome and transcriptome analyses of 1,699 
paediatric leukaemias and solid tumours. Nature 2018;555(7696):371-76. doi: 
10.1038/nature25795 [published Online First: 2018/02/28] 
23. Forrest SJ, Geoerger B, Janeway KA. Precision medicine in pediatric oncology. Curr Opin Pediatr 
2018;30(1):17-24. doi: 10.1097/MOP.0000000000000570 
24. Di Resta C, Galbiati S, Carrera P, et al. Next-generation sequencing approach for the diagnosis of 
human diseases: open challenges and new opportunities. EJIFCC 2018;29(1):4-14. [published 
Online First: 2018/04/30] 
25. Xuan J, Yu Y, Qing T, et al. Next-generation sequencing in the clinic: promises and challenges. 
Cancer Lett 2013;340(2):284-95. doi: 10.1016/j.canlet.2012.11.025 [published Online First: 
2012/11/19] 
26. Oberg JA, Glade Bender JL, Sulis ML, et al. Implementation of next generation sequencing into 
pediatric hematology-oncology practice: moving beyond actionable alterations. Genome 
Med 2016;8(1):133. doi: 10.1186/s13073-016-0389-6 [published Online First: 2016/12/23] 
27. Wise J. Genome sequencing of children promises a new era in oncology. BMJ 2019;364:l105. doi: 
10.1136/bmj.l105 [published Online First: 2019/01/08] 
28. Pinto N, Cohn SL, Dolan ME. Using germline genomics to individualize pediatric cancer 
treatments. Clin Cancer Res 2012;18(10):2791-800. doi: 10.1158/1078-0432.CCR-11-1938 
29. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation 
associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 
2009;301(4):393-403. doi: 10.1001/jama.2009.7 
30. Abaji R, Ceppi F, Patel S, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic 
leukemia patients identified using whole-exome sequencing. Pharmacogenomics 
2018;19(15):1181-93. doi: 10.2217/pgs-2018-0093 [published Online First: 2018/09/07] 
 
